Verified: 13 September 2026 05:30 am IST
Industry: Pharmaceutical Manufacturing (APIs & Nutraceuticals)
Jurisdiction: India
Primary Regulators: Ministry of Corporate Affairs (MCA), SEBI, & Central Drugs Standard Control Organization (CDSCO)
Important Safety Warning: Beware of fake customer service numbers on Google. Only use official channels. Scammers frequently buy ads to promote fraudulent phone numbers. Divi’s Laboratories staff will never ask for your bank details, UPI PIN, or password for a “refund processing fee” or “shareholder dividend transfer.”
Level 1: Customer Support (Initial Complaint)
How to complain: Do not search for random phone numbers online. For initial corporate inquiries, institutional complaints, or shareholder issues, call the Divi’s Laboratories Corporate Headquarters directly at 040-23786300 or 040-66966300. For written disputes, email the central information desk at info@divislabs.com. For specific shareholder or secretarial grievances, email mail@divislabs.com. If the dispute involves their nutraceutical ingredients division, you should email marketing@divisnutra.com. For online inquiries, use the official web portal at divislabs.com/contact/. Ensure you receive a formal acknowledgment or reference number for your written communication.
Availability: Standard business hours for the corporate office are Monday to Friday, 9:00 AM to 6:00 PM IST.
Timeline: Standard resolution time for general inquiries or shareholder disputes is typically 7 to 15 business days.
Level 2: Formal Corporate Escalation (Notice of Dispute)
Who to contact: If the initial desk (Level 1) fails to resolve your issue within the stipulated time, you must escalate the matter formally. You can send a formal written complaint via registered post to the Company Secretary / Compliance Officer at their Registered Corporate Office: Divi’s Laboratories Limited, 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad - 500032, Telangana, India.
Timeline: You should legally provide the corporate office a 30-day window to investigate and respond to a formal written grievance before escalating to external regulatory authorities.
Level 3: Regulatory Authority (Government Ombudsman)
Authority: Ministry of Corporate Affairs (MCA), SEBI, or CDSCO.
Portal/Contact: If Divi’s Laboratories fails to provide a satisfactory resolution within 30 days, your escalation path depends on the specific grievance:
- For Shareholder & Investor Disputes: File a grievance with the Securities and Exchange Board of India (SEBI) via the SCORES portal (
scores.sebi.gov.in) or contact the Ministry of Corporate Affairs (MCA) via the MCA21 portal (mca.gov.in). - For B2B Pharmaceutical Quality/API Issues: File a quality complaint with the Central Drugs Standard Control Organization (CDSCO) by calling their Toll-Free number 1800-111-454 or emailing
dci@nic.in. - For General Service Disputes: File a grievance with the National Consumer Helpline (NCH) by calling 1915 or using the portal at
consumerhelpline.gov.in.
Level 4: Legal Action (Final Step)
Pre-Litigation: Ensure you have documented all previous correspondence, transaction invoices, shareholder folios, and email trails. Send a formal Legal Notice via an advocate to Divi’s Gachibowli registered office in Hyderabad, providing a standard 30-day window for settlement.
Court/Arbitration: If the legal notice is ignored and the resolution is still unsatisfactory, the final step is approaching the judicial system. You can file a formal complaint through the unified e-Jagriti portal (e-jagriti.gov.in) to approach the District Consumer Disputes Redressal Commission based on your jurisdiction (if you qualify as a “consumer” under the Act) or pursue commercial arbitration/NCLT proceedings for B2B/shareholder disputes.
Key insight: Because Divi’s operates heavily in the B2B API space, standard consumer courts (like e-Jagriti) will often reject cases if the complainant is determined to be a commercial entity rather than an end-consumer. Commercial arbitration is usually required for B2B supply disputes.
Community Action: Is Divi’s Laboratories ignoring a shareholder dividend issue or a corporate compliance complaint? Reply below (do not share your DEMAT account details, folios, or passwords), and our community will point you to the right resources!